Plasma Levels of hsa-miR-619-5p and hsa-miR-1184 Differ in Prostatic Benign Hyperplasia and Cancer

E. N. Knyazev; K. A. Fomicheva; D. S. Mikhailenko; K. M. Nyushko; T. R. Samatov; B. Ya. Alekseev; M. Yu. Shkurnikov

doi:10.1007/s10517-016-3357-7

Plasma Levels of hsa-miR-619-5p and hsa-miR-1184 Differ in Prostatic Benign Hyperplasia and Cancer

Authors: Knyazev E.N.¹, Fomicheva K.A.², Mikhailenko D.S.², Nyushko K.M.², Samatov T.R.¹, Alekseev B.Y.², Shkurnikov M.Y.¹^,2
Affiliations:
1. BioClinicum Center Research and Development Company
2. Medical Radiology Center
Issue: Vol 161, No 1 (2016)
Pages: 108-111
Section: Article
URL: https://journals.rcsi.science/0007-4888/article/view/237158
DOI: https://doi.org/10.1007/s10517-016-3357-7
ID: 237158

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Statistics

Abstract

Peripheral blood plasma profiles of circulating microRNA expression were analyzed in patients with prostatic cancer and benign hyperplasia. In prostatic cancer, significant increase in hsa-miR-619-5p and hsa-miR-1184 microRNA expression and significant decrease in hsalet-7b-5p and hsa-let-7c-5p microRNA expression were observed. The role of the relationship between the microRNA expression and the activities and functions of host genes with introns encoding these microRNA is discussed.